Table 5 Multivariate analysis of predictive factors for benefit from Metronomic treatment in patients undergoing metronomic zoledronic acid
Clinical and biochemical factor | Patient population | Multivariate | |||
|---|---|---|---|---|---|
| Â | Â | Variables in model | Backward selection | ||
| Â | Â | HR (99% CI) | P | HR (99% CI) | P |
DFI (year) | > 2 vs ≤ 2 | 1.811 (0.788-4.161) | 0.026 | -- | |
ER status | + vs - | 0.753 (0.281-2.014) | 0.459 | -- | |
Numbers of previous chemotherapy | ≤ 2 vs > 2 | 0.414 (0.130-1.136) | 0.050 | -- | |
Baseline CEA (ug/L) | ≤ 10 vs > 10 | 1.633 (0.629-4.241) | 0.186 | -- | |
Baseline CA 15-3 (U/mL) | ≤ 25 vs > 25 | 1.283 (0.433-3.800) | 0.554 | -- | |
Baseline NTx (nM BCE) | ≤ 18 vs > 18 | 1.645 (0.652-4.150) | 0.166 | 2.309 (1.067-5.012) | 0.005 |